CEL-SCI Corp. (CVM) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

161.16 k

Shareholding (Mar 2025)

FII

0.36%

Held by 16 FIIs

DII

95.15%

Held by 5 DIIs

Promoter

0.00%

How big is CEL-SCI Corp.?

22-Jun-2025

As of Jun 18, CEL-SCI Corp. has a market capitalization of 11.91 million, with net sales of 0.00 million and a net profit of -26.61 million over the latest four quarters. As of Sep 24, the company reports shareholder's funds of 12.87 million and total assets of 26.99 million.

What does CEL-SCI Corp. do?

22-Jun-2025

CEL-SCI Corporation focuses on researching and developing cancer treatments and other diseases by harnessing the immune system, operating as a micro-cap company in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported a net profit loss of $7 million and has a market cap of $11.91 million.

Who are in the management team of CEL-SCI Corp.?

22-Jun-2025

As of March 2022, the management team of CEL-SCI Corp. includes CEO Geert Kersten, along with independent directors Bruno Baillavoine, Robert Watson, and Peter Young.

Is CEL-SCI Corp. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, CEL-SCI Corp. shows a mildly bearish trend, with mixed technical indicators and significant underperformance compared to the S&P 500, reflecting a year-to-date return of -25.65% versus the S&P's 12.22%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 83 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.09

Return on Equity

-388.39%

Price to Book

11.78

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-43.37%

6 Months

114.41%

1 Year

-78.61%

2 Years

-94.03%

3 Years

-92.24%

4 Years

-97.99%

5 Years

-98.75%

CEL-SCI Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-17.17%

EBIT Growth (5y)

0.96%

EBIT to Interest (avg)

-21.94

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.05

Sales to Capital Employed (avg)

0.00

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

14.34%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.53

EV to EBIT

-0.48

EV to EBITDA

-0.57

EV to Capital Employed

1.50

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-309.71%

ROE (Latest)

-341.14%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 8 Schemes (4.49%)

Foreign Institutions

Held by 16 Foreign Institutions (0.36%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 17.39% vs 17.86% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.50",
          "val2": "-5.70",
          "chgp": "21.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.70",
          "val2": "-6.90",
          "chgp": "17.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2024 is 16.46% vs 12.26% in Sep 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-22.40",
          "val2": "-27.50",
          "chgp": "18.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.70",
          "val2": "0.70",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-26.90",
          "val2": "-32.20",
          "chgp": "16.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.50

-5.70

21.05%

Interest

0.20

Exceptional Items

-0.00

0.00

Consolidate Net Profit

-5.70

-6.90

17.39%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 17.39% vs 17.86% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'24

Sep'24

Sep'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-22.40

-27.50

18.55%

Interest

0.70

Exceptional Items

0.00

Consolidate Net Profit

-26.90

-32.20

16.46%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2024 is 0.00% vs 0.00% in Sep 2023

Consolidated Net Profit

YoY Growth in year ended Sep 2024 is 16.46% vs 12.26% in Sep 2023

All Annual Results

Company CV

About CEL-SCI Corp.

CEL-SCI Corp.

Pharmaceuticals & Biotechnology

CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.

Company Coordinates

Company Details

8229 Boone Blvd Ste 802 , VIENNA VA : 22182-2634

Tel: 1 703 5069460

http://www.cel-sci.com/

Registrar Details

CEL-SCI Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is CEL-SCI Corp.?

Watch in Real-Time

What does CEL-SCI Corp. do?

Who are in the management team of CEL-SCI Corp.?

Is CEL-SCI Corp. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Sep'24

About CEL-SCI Corp.

Company Coordinates